Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
about
Ivabradine as adjuvant treatment for chronic heart failureIvabradine as adjuvant treatment for chronic heart failureRecent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsThe Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta-analysis With Trial Sequential Analysis of More Than 40000 PatientsRecent advances in treatment of heart failureMedical management of chronic stable anginaAddressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of IvabradineVascular endothelial dysfunction and pharmacological treatmentHCN channels and heart rateIvabradine, coronary artery disease, and heart failure: beyond rhythm controlSacubitril/valsartan in heart failure: latest evidence and place in therapyAdvances in the management of heart failure: the role of ivabradinePresent and future pharmacotherapeutic agents in heart failure: an evolving paradigmHeart rate and use of beta-blockers in stable outpatients with coronary artery diseaseManagement standards for stable coronary artery disease in India.Heart Rate Reduction With Ivabradine Protects Against Left Ventricular Remodeling by Attenuating Infarct Expansion and Preserving Remote-Zone Contractile Function and Synchrony in a Mouse Model of Reperfused Myocardial Infarction[National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study.Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry.Ivabradine for the treatment of stable angina pectoris in octogenarians.Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients.Pacemaker current inhibition in experimental human cardiac sympathetic activation: a double-blind, randomized, crossover study.Risk-benefit assessment of ivabradine in the treatment of chronic heart failureClinical presentation and management of stable coronary artery disease in Austria.Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials.ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathyEffect of dronedarone on Na+, Ca2+ and HCN channels.Optimized treatment and heart rate reduction in chronic heart failure.Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series.Impact of chronic atrial fibrillation in patients with severe heart failure and indication for CRT: data of two registries with 711 patients (1999-2006 and 2007-6/2008).Elevations in time-varying resting heart rate predict subsequent all-cause mortality in older adults.Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitusPotential additive effects of ticagrelor, ivabradine, and carvedilol on sinus node.Resting heart rate and risk of sudden cardiac death in the general population: influence of left ventricular systolic dysfunction and heart rate-modulating drugs.A prospective population study of resting heart rate and peak oxygen uptake (the HUNT Study, Norway)
P2860
Q24185982-5837A8AB-AD85-467D-A846-9912E8CCF93CQ24201614-0EE02322-C50A-479D-977C-51B6B8E643D5Q24605881-FF3AAA4C-7895-4304-8139-8090503E64D0Q24614627-CDE771E7-6E9F-492E-8134-7C68ACB54AA9Q26741956-9202F886-3A69-4C76-BE5D-94B85DF5D7CCQ26766223-58DDA51A-3C93-4A85-95EB-1E1B47A98DC8Q26773268-8B4EB0ED-13A1-4B15-9DF6-7CCEAFF6CF48Q26773370-9C40249A-A83D-44C4-A8D5-C389C825DF01Q26774561-9C95E8FF-8748-427E-ACBB-735B26A58955Q26859318-0AFE6540-7170-4DCA-B812-7A4C1F5273E1Q26865770-A17D3DC1-5708-4B9A-A6BF-D82955639BC8Q28070191-F419CC66-0DDC-488E-9BEB-73F2F9A4A79FQ28072418-D9F55DFB-67CA-4242-81B0-FC2153AB8CC1Q28077186-FB2E030A-48F3-4FBA-BD52-FDF57DB9417DQ28730142-4790149A-C294-4C39-8D09-6FF1314C57C7Q30239853-5F72DDCF-EB81-4AC5-BBA8-A182A5A5DB3FQ30276924-341A0F12-8800-483A-A920-6BADC8C7133DQ30313892-2304C583-A18F-4770-8F97-94C9D16FB871Q30318221-D9AA6BDE-12A1-4081-B7EE-E7E80CA782AAQ30318280-7DD2442E-CFD6-4AEC-A874-ED2F423A7563Q30318384-D51FD5A9-45C7-4F43-8C94-37A0722ABBF0Q30583012-8CA3188E-4C07-4D13-9870-B90C17D5CE8DQ30608315-3716B0D5-80E6-47A6-A17D-0972B27D1B1DQ30844230-342C8B42-F16D-49C3-8C98-91505278B204Q33159163-229A9F92-CC73-4DB6-AE58-4344BFEA0EE3Q33162534-46CC1649-D115-495F-A185-143C81A21B11Q33163797-F7A0DE68-D29D-4E06-B71D-B67B7B8E31EEQ33568592-35865B95-DFF9-44A6-834F-0D2D2DB4C62CQ33610452-672CE172-0F63-4BC7-9862-5A3F8278A86BQ33617828-586C3740-A92A-43E1-BD8F-516CF9CA44B8Q33647497-12464BEE-5584-494B-97FE-0C15222A1EF8Q33807062-6D9A6AC0-8DDE-40E2-84A6-63902F36F884Q33843442-52F6B93F-AFD3-4931-B985-6F30632D8A64Q33937346-C4CE4F97-315D-4A25-A1BB-D08F00ADB376Q34096966-36C28224-880B-4CBB-B5F6-7C073CDD8065Q34143395-926F2D94-30BF-47B3-BA64-CC7AC5704D57Q34222683-75966EB1-713A-4A67-8F17-44650FDEF412Q34330526-E76D23D4-14AC-4A31-950E-6522876DB984Q34345139-1C046B5B-2815-4B76-9F6D-4A69D0BC14F9Q34427892-B6371C4C-FEC1-421E-B3A2-974CF205D7FD
P2860
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@ast
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@en
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@nl
type
label
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@ast
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@en
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@nl
prefLabel
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@ast
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@en
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@nl
P2093
P921
P1433
P1476
Ivabradine for patients with s ...... ind, placebo-controlled trial.
@en
P2093
BEAUTIFUL Investigators
P Gabriel Steg
Roberto Ferrari
P304
P356
10.1016/S0140-6736(08)61170-8
P407
P577
2008-08-29T00:00:00Z